Shah Gilani's Archive
Shah Gilani
Wall Street superstar and former hedge fund manager Shah Gilani is the Chief Investment Strategist of Manward Press and at the helm of the Manward Money Report newsletter and the Launch Investor and Alpha Money Flow trading services. He’s a sought-after market commentator and has appeared on CNBC, Fox Business and Bloomberg TV. He’s also been quoted in The Wall Street Journal, The New York Times and The Washington Post, and he’s had columns published in Forbes.
In 1982, he launched his first hedge fund from his seat on the floor of the Chicago Board Options Exchange. He worked in the pit as a market maker when options on the S&P 100 Index first began trading… and was part of a handful of traders who laid the technical groundwork for what would eventually become the CBOE Volatility Index (VIX). He also ran the futures and options division at the largest retail bank in Britain. Shah gained notoriety for calling the implosion of U.S. financial markets (all the way back in February 2008) AND the mega bull run that followed.
Now at the helm of Manward, Shah is focused tightly on one goal: To do his part to make subscribers wealthier, happier and more free.
Rebuilding America’s Backbone – The Next Capital Wave is in the Capitol’s Hands
An old adage tells us that “Cs get degrees.”
But middling marks like that will never put you on the honor roll.
And that’s America’s problem right now – as well as its challenge.
Plug into This Options Play Before Earnings Disappoint
Plug Power Inc. (NasdaqCM:PLUG) reports earnings this Thursday, May 20, 2021, after the bell. If the company disappoints on their numbers the stock could tumble.
3 Toxic Stocks to Sell-Off Before It’s Too Late
In this week’s BS.H, I’m tackling three noxious stocks – stocks considered Wall Street darlings just because they were in the right place at the right time – that have many investors hook, line, and sinker.
But don’t be fooled, no matter how clean they look on the outside, these stocks are as toxic as they come. If you own one of these, you need to think about selling immediately and don’t look back.
Click the video below to find out just which stocks could be holding you back.
Four Ways to Cash in on the $29.6 Billion Psychedelic ‘Shroom Boom
The number of stocks in the psychedelics space, no pun intended, is expanding like all good universes.
There are already more than 50 publicly traded companies pursuing the billions in new market opportunities in the hallucinogen-based treatment market – a “New Biotech” opportunity I like to refer to as the ‘Shroom Boom.
A lot of these companies are innovative cousins to conventional biotech firms. Like their better-known counterparts, these upstarts are pursuing new drugs, compounds, therapies, and treatment protocols, to arrest or even cure mental illnesses, substance abuse, pain, PTSD, and even chronic brain disorders. The big difference: These ‘Shroom Boom ventures are incorporating psychedelics in their research and trials.
I’ve also identified “pick-and-shovel” companies whose path to sales-and-profits relies on sourcing and manufacturing psychedelics or building infrastructure, like clinics and training therapists.
Here are four companies I like. Two cover the research, trials, and biotech potential of psychedelics. The other two are pick-and-shovels plays that have ID’d innovative ways to apply their trade on this new trend.
Forget Pot Stocks – It’s Time to Cash-In on the Psychedelics ‘Shroom Boom
I came of age in the late ’60s and early ’70s, which means I’m no stranger to recreational drugs, from pot to psychedelics. Like, I’ve seen things, man – and could tell you some stories. And I was so fascinated by what I saw that I got with the program, and dug deep into the story behind the story.
LSD was still legal. Research was going full bore. And I understood these drugs had promise – real promise.
That all ended in October 1968, when the U.S. made it illegal to possess the hallucinogen. And thanks to that, the research slowly died.
But psychedelics are making a comeback. And I’m groovin’ on all the hip research and FDA trials, and the crazy number of publicly traded companies chasing riches in the psychedelics rainbow.
Can you dig it? You should. There’s evidence psychedelics have the potential to arrest – and maybe even cure – a host of disorders from depression to brain trauma. And if these drugs work – and if you’re into the right stocks – you could end up on the trip of your life, and watch as your portfolio gets high … and I mean really high, man.
If you’re watching the markets and looking at this “new biotech,” you’re no doubt hearing about the tremendous promise of the marijuana legalization, the cannabis market – and the pot-stock boom.
Maybe you missed the pot-stock run the first time around. Or maybe you can’t bring yourself to invest in something in something that’s been maligned so much for so many years.
Don’t sweat it – because here’s the heavy truth: The real opportunity is with psychedelics.
Call it the Shroom Boom.
And I’m going to lay it on you here…
How to Play BABA Calls and Tap into Another Triple-Digit Profit Opportunity
Last Tuesday, I mentioned I liked buying the MRNA June 18, 2021 $165/170 Put Spread to take advantage of what looked like an opportunity for a quick reversal in Moderna, Inc. (NasdaqGS:MRNA).
By Thursday, just two days later, shares of MRNA had dropped as much as 23%, and the MRNA June 18, 2021 $165/170 Put Spread had gained more than 400%
The Latest from the Watchlist – Vaccine Stock Flops, Chinese Market Giants, and the Movie Theater Revival
Now I don’t mean to say, “I told you so,” but Varney & Co. didn’t call me the “Man Who Calls It All” for nothing. Just as I predicted a few months back, Pfizer (PFE) stands to lose its COVID-19 vaccine patents and their company’s profitability is about to tank. Hard.
That’s leaves us a wide opening to make some serious profits with its downfall, but that’s not all on my watchlist today.
Early this morning, you should have gotten my watchlist update. Those will be coming in hot every Monday before the opening bell, so make sure to keep your eyes peeled!
If you missed it, don’t worry. You can read all about my favorite stocks for the week here.
Or, just click the video below because I am back with yet another video to take an even deeper dive into these stocks. PFE may be on its way out, but two other heavy-hitting Chinese stocks, NIO and BABA, are going to take off before the year is out.
3 Sells, 2 Holds, and 1 BUY on Today’s Biggest Tech Movers
Tech stocks own the market, but that doesn’t mean you should go blindly into them. That’s what most people will do – but you shouldn’t.
Putting the hype before the horse means you’ll almost always wind up with losers disguised as the next Amazon. So, in today’s BS.H, you’ll hear about three tech stocks that run the gauntlet from the good, the bad, and the exceptionally ugly. I go over their profits, their debts, and whether they’re fit to buy, sell, or hold.
Options Tuesday: Taking Profits Off of Moderna’s Tower of Terror
With COVID-19 vaccination programs rolling along, it might well be assumed that any stock tied to vaccinations is on a one-way trip higher.
Not so fast. There’s that whole thing about “assuming,” and I think you know what they say…
This Week’s BS.H – What to Do with Two of the Biggest Pot Stocks with Legalization Afoot
With legalization around the corner for so many states in the U.S., several of you were asking: “To buy or not to buy?”
That is the question… A few years back I would have given a resounding heck no. But I have to say, I’m starting to change my mind about two of the biggest pot stocks on the market right now.
And I’ll tell you why in today’s BS.H, where I tell you what to buy, sell, or hold.